A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Status:
Recruiting
Trial end date:
2024-05-16
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicenter, phase III study
Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO
Alfa 60000 UI/week for at least 12 weeks:
- Either at diagnosis Or
- at the Hb threshold chosen for RBC transfusions (must be < 9g/dl)